Repro Med Systems, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 11, 2021 at 05:07 pm EDT
Share
Repro Med Systems, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 5.528 million compared to USD 7.708 million a year ago. Operating loss was USD 1.381 million compared to USD 1.032 million a year ago. Net loss was USD 1.124 million compared to USD 1.076 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. For the half year, sales was USD 10.959 million compared to USD 14.038 million a year ago. Operating loss was USD 3.594 million compared to USD 449,178 a year ago. Net loss was USD 2.400 million compared to USD 626,610 a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.02 a year ago.
KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. It is focused on home and specialty infusion solutions. The Companyâs focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patientâs subcutaneous tissues can tolerate and what the system delivers.
KORU MEDICAL SYSTEMS, INC. 
